Navigation Links
PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference
Date:10/6/2008

the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, products incorporating eFlow Technology reduce the burden of taking daily, inhaled treatments. eFlow Technology and products based on it are proprietary to PARI Pharma.

PARI Pharma partners with pharmaceutical companies to develop new or improved therapies with eFlow Technology and other advanced delivery platforms. Investigational eFlow Nebulizer Systems are optimized per investigational drug product and are currently in clinical trials for asthma, cystic fibrosis, respiratory syncytial virus (RSV) infection, and treatments for lung transplant patients among other indications.

About PARI Pharma

PARI Pharma focuses on the development of aerosol delivery devices and therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma develops treatments for pulmonary and nasal administration optimized with advanced delivery technologies, such as eFlow Technology.

PARI Pharma provides comprehensive inhalation drug development, including nebulizer formulation development and optimization, CMC, analytics, aerosol characterization, clinical protocol development, and regulatory guidance. PARI Pharma has several clinical development programs ongoing, either partnered or on its own. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany with a major presence in the United States. Online at http://www.paripharma.com

Additional information on eFlow Technology is available by contacting Kirsten Ayars at 805-452-7909 or Geoff A. Hunziker at 831-372-3580.


'/>"/>
SOURCE PARI Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Calif. (PRWEB) May 04, 2015 ... Medical Group today launched a new initiative at ... the next generation of physicians committed to advancing ... Para Ser Medicos, or Preparing Students to Be ... initiative that will provide scholarships, mentorship and internship ...
(Date:5/4/2015)... May 04, 2015 Getting patients to ... their health is critical to achieving the “triple aim” ... costs, but this will require a shift in thinking ... demands that health systems move beyond their traditional boundaries ... part in the third live meeting of the ...
(Date:5/4/2015)... American Telemedicine Association (ATA) today released an update to ... coverage and reimbursement, and physician practice standards and licensure. ... last September, many state regulating bodies responded by looking ... in their state,” said Jonathan Linkous, CEO of ATA. ... ATA reevaluated the indicators for each state and issued ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 The ... as baby boomers join the ranks of senior citizens ... demand on an already over-burdened healthcare system. Additionally, as ... staff to replace them. Per the U.S. Census Bureau, ... expected to increase 75% by 2050 while those 25 ...
(Date:5/4/2015)... CA (PRWEB) May 04, 2015 ... is now offering a more comfortable and attractive alternative ... restoration of choice for those who have lost teeth. ... can feel insecure or slip at the worst possible ... eats or talks. They can also painfully pinch or ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2
... Process Commences for Issuance of Certification to Operate ... Healthcare,Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), a ... physicians,today announced that all applications for the launch ... have been filed and accepted for review by ...
... advance in waking up since coffee, SPARTA, N.J., April ... morning feeling refreshed and ready to go, you,re not alone. ... and even driving ability. Fortunately, a unique and ingenious,solution has ... take before,bedtime that will help you to wake up in ...
... 2008 Throw down your,mop and broom! Spring cleaning ... important -- your body. Daily exposure to thousands of,toxins ... produce a toxic load in the body that may ... http://www.newscom.com/cgi-bin/prnh/20080408/NYFNSF06 ), "Ideally, you should cleanse with ...
... NORWALK, Conn., April 8, 2008 Morris "Mo" Moses ... could for Mo,s health. A,Type II diabetic, with multiple ... bottom of his right foot which just wouldn,t go,away., ... of CT, and a,board-certified foot surgeon at Norwalk and ...
... During the,Association of periOperative Registered Nurse,s (AORN) ... approved the development of,an electronic Standardized Perioperative ... the creation of a standardized record that ... SPR will,incorporate AORN,s standardized nursing vocabulary, the ...
... ALB ) will hold its quarterly conference call to ... ET., This call is being webcast by Thomson/CCBN and ... in the Investor,Information section., To listen ... In # 800-591-6942 International Dial In ...
Cached Medicine News:Health News:Phyhealth HMO Applications Accepted by All Required Federal and State Agencies 2Health News:Tired Mother Invents Pill to Wake You Up On Time 2Health News:Spring Clean Your Body for the Perfect Cleanse 2Health News:Living Cell Treatment Heals Diabetic Foot Sores Fast 2Health News:AORN Announces Initiative to Develop a Standardized Electronic Healthcare Record for the Perioperative Setting 2Health News:AORN Announces Initiative to Develop a Standardized Electronic Healthcare Record for the Perioperative Setting 3Health News:Albemarle Corporation's First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET 2
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
(Date:5/4/2015)...  Oncobiologics, Inc., a biotherapeutics company focused on ... completed the construction of its GMP commercial launch ... Cranbury, New Jersey . The ... to utilize multiple technologies that enable rapid deployment ... use of the latest single-use technologies, the facility ...
(Date:5/4/2015)...   HeartWare International, Inc . (NASDAQ: HTWR ), ... that are revolutionizing the treatment of advanced heart failure, today ... scheduled to present at the Bank of America Merrill Lynch ... on Thursday, May 14, 2015, at 10:00 a.m. PT ... Company,s presentation at the conference will be available via a ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... - Results suggest pirfenidone may provide meaningful clinical benefit ... efficacy and safety reported -- Conference Call and Webcast ... DIEGO, May 19 InterMune, Inc. (Nasdaq: ... 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic ...
... that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment ... placebo in patients with Bipolar I Disorder. Results of ... medical meeting. Bipolar Disorder is a brain disorder ... and ability to function. It is often characterized by ...
Cached Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: